Literature DB >> 3207357

Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches.

K Saito1, S Markowitz, M A Moskowitz.   

Abstract

Although the ergot alkaloids (ergots) are useful drugs for the acute treatment of migraine headaches, their mechanism of action remains obscure. When administered to rats in clinically relevant doses, ergots blocked the development of neurogenic plasma extravasation in dura mater. Plasma extravasation was induced by depolarization of perivascular axons following capsaicin injection or unilateral electrical stimulation of the trigeminal nerve. The ergot action could not be accounted for by vasoconstriction alone because neurogenic plasma leakage was not blocked by angiotensin or phenylephrine. Furthermore, ergots did not block plasma extravasation induced by administering sensory neuropeptides that mediate enhanced permeability. We propose that the therapeutic effects of ergots in vascular headaches may result from peripheral blockade of small fiber (C or A-delta)-dependent neurogenic inflammation within the dura mater.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207357     DOI: 10.1002/ana.410240607

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  33 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  CP-93,129, a potent and selective 5-HT1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater.

Authors:  T Matsubara; M A Moskowitz; B Byun
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 3.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

4.  [Animal models and their results in relation to the therapy of migraine].

Authors:  H Kaube; V Limmroth
Journal:  Schmerz       Date:  1996-06-17       Impact factor: 1.107

Review 5.  Neuropeptide gene expression and neural activity: assessing a working hypothesis in nucleus caudalis and dorsal horn neurons expressing preproenkephalin and preprodynorphin.

Authors:  G R Uhl; T Nishimori
Journal:  Cell Mol Neurobiol       Date:  1990-03       Impact factor: 5.046

6.  The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats.

Authors:  S L Shepheard; D J Williamson; R G Hill; R J Hargreaves
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

Review 7.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

8.  Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms.

Authors:  X J Yu; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 9.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.

Authors:  M O den Boer; C M Villalón; J P Heiligers; P P Humphrey; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.